NE Fresno Location

Eye Medical Center of Fresno

Macular Degeneration

Geographic Atrophy

Atrophy

Macular Edema

Wet Macular Degeneration

Retinal Vein Occlusion

Diabetic Retinopathy

Hemorrhage

Edema

Vitreous Hemorrhage

KSI-301

Aflibercept

Vitrase

Avacincaptad pegol

Zimura

Kodiak Sciences

Astellas

Bausch + Lomb

Iveric Bio

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment (either avacincaptad pegol or Sham).

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Eye Medical Center of Fresno | NE Fresno Location

Site insights

Work at this site?

Active trials

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Trial sponsors